Tarsila do Amaral Seamstresses (Costureiras), 1950 Oil on canvas 73.3 × 100.2 cm Museu de Arte Contemporânea ... Entre os vossos dentes’ at Centro de Arte Moderna, Lisbon, Portugal (April ...

China's trade surplus grew to $104.84 billion in December, as exports rose faster than expected, according to official customs data released on Monday. Chinese factories rushed to complete orders ...

Museu de Arte Contemporânea and Museu de Arte Moderna. Travelers frequently describe Ibirapuera Park as an "oasis" and say it is a relaxing place to spend the day walking through the park ...

Ron Mueck’s En Garde (2023) will be exhibited for the first time in the UK at Thaddaeus Ropac, London. The work was conceived ...

A new art experience opens in Portugal in the spring of 2025. It's an immersive art exhibit and a luxury hotel, the first of ...

including the Museu de Arte de São Paulo, Shopping Cidade São Paulo and Parque Trianon. Past travelers said walking this wide avenue allows you to get a feel for what life is like in the city.

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...